radical surgery + CAMRELIZUMAB + Paclitaxel + CISPLATIN for uterine cervical neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Mar 2024: Trial registered, NCT06288360
  2. 12 Sep 2024: Trial started, NCT06288360

The trials

NCT06288360: Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

State
Under way
Phase
Phase 2
People
40 planned
Started
12 Sep 2024
Primary completion
31 Dec 2025
Arms
Neoadjuvant chemotherapy plus camrelizumab (NACI)
Results
None posted
  1. 1 Mar 2024: Trial registered
  2. 12 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.